Blog
Engineering Smarter ADCs: Novel Linkers for Better Safety and Efficacy
Antibody-drug conjugates (ADCs) are complex therapeutics that link antibodies to cytotoxic payloads, offering a targeted approach to mitigate the systemic toxicity of conventional chemotherapy. Despite rapid progress in ADC engineering, significant challenges remain,...
One Antibody, Many Tasks: The Rise of Multi-Specific ADCs
Multispecific ADCs: Solutions to Oncology's Toughest Hurdles Antibody drug conjugates (ADCs) combine carefully engineered monoclonal antibodies with chemotherapy drugs, allowing for targeted therapeutic delivery to cancer cells. Targeting tumors with ADCs can mitigate...
Spotlight on Psoriasis – Advanced IL-23 Inhibitor Preclinical Screening Assays for Better Outcomes for Patients
Psoriasis: Patient Impact and the Path to Innovation Psoriasis is more than a skin condition, it is often a lifelong, systemic autoimmune disease that may increase the risk of other serious health complications such as heart disease and diabetes, and have a...
Targeted Protein Degradation: Bridging the Gap in PROTAC Development
Unlocking the Potential of Targeted Protein Degradation In the realm of novel therapeutics, targeted protein degradation has serendipitously emerged as a game-changer, transforming "undruggable" proteins into viable candidates for therapeutic intervention. By...
Bold Launch of Boston R&D Center of Excellence
A Beacon of Innovation and Resilience in Biotech's Challenging Landscape This article provides an overview of the recent grand opening of ChemPartner’s Boston R&D Center of Excellence, written for the broader global scientific community who may not have been able...
Dual Targets, Double Impact: Advancing HER2 x TROP2 Bispecific ADCs in Preclinical Development
Homing in on the tumor: the magic bullet of cancer therapy Antibody-drug conjugates (ADCs) have revolutionized oncotherapy, achieving significant clinical success in multiple cancer types. Hailed as a “magic bullet” of precision medicine, ADCs improved therapeutic...
Impact Starts in the Lab: Using Preclinical Models to Combat Autoimmune & Autoinflammatory Arthritis
ChemPartner brings awareness about Autoimmune & Autoinflammatory Arthritis on 2025 AiArthritis Day Invisible and misunderstood: how it is to live with an autoimmune disease? “I think the hardest part of having an autoimmune...
From Mutation to Metastasis: Preclinical Assay Platform for KRAS G12C Targeted Therapy
Three-decade long saga brings promise and breakthrough for better therapies Kirsten rat sarcoma (KRAS) has been long recognized as the most commonly mutated protooncogene, and under active exploration in cancer research for the...
Common Preclinical ADC Development Mistakes (And How to Avoid Them)
Understanding the Complexities of Antibody-Drug Conjugate (ADC) Development Antibody-drug conjugates (ADCs) are at the forefront of targeted cancer therapies, offering a powerful combination of monoclonal antibody specificity and...
Employee Spotlight: Hu Liu, PhD
Employee Spotlight Our employee spotlight series celebrates the accomplishments and expertise of our valued scientists and staff. Hu Liu Hu Liu, PhD Director of Biologics Discovery Q&A with Dr. Liu What is your favorite part...
The Crucial Role of Cell Line Development in Fueling Therapeutic Advancements
In the dynamic world of biopharmaceutical research, cell line development and banking is pivotal in paving the way for groundbreaking therapies. Cell lines are stable cell cultures developed from a single cell, thus consisting of cells with a uniform genetic makeup....
Harnessing the Power of Antibody-Drug Conjugates (ADCs) with Expertise and CROs
In the ongoing battle against cancer, antibody-drug conjugates (ADCs) shine as a beacon of hope. These resourceful molecules combine the precision of monoclonal antibodies with the potency of cytotoxic drugs, making them a formidable weapon against drug resistance and...
Headquarters
1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203
Contact Us
China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000